Crohn's Disease and the Risk of Cancer

Evie Carchman

doi:10.1055/s-0039-1683923

Clinics in Colon and Rectal Surgery, Inhaltsverzeichnis

Clin Colon Rectal Surg 2019; 32(04): 305-313
DOI: 10.1055/s-0039-1683923

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Crohn's Disease and the Risk of Cancer

Evie Carchman

¹Department of Surgery, University of Wisconsin, Madison, Wisconsin

› Institutsangaben

Abstract

Crohn's disease is associated with various intestinal and extraintestinal malignancies. This article reviews the current literature regarding Crohn's disease and subsequent risk of cancer formation. Recognition of risk factors (both modifiable and unmodifiable) is essential for prevention and appropriate screening. Future investigations into the molecular mechanisms associated with Crohn-related malignancy will provide additional insight into carcinogenesis, potential for early intervention, and identification of at-risk patients.

Keywords

Crohn's disease - malignancy - cancer - inflammatory bowel disease

Volltext

Referenzen

References
1 Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011; 17 (01) 423-439
2 Hovde Ø, Moum BA. Epidemiology and clinical course of Crohn's disease: results from observational studies. World J Gastroenterol 2012; 18 (15) 1723-1731
3 Biancone L, Armuzzi A, Scribano ML. , et al; Italian Group for the study of Inflammatory Bowel Disease. Inflammatory bowel disease phenotype as risk factor for cancer in a prospective multicentre nested case-control IG-IBD study. J Crohn's Colitis 2016; 10 (08) 913-924
4 Hovde O, Hoivik ML, Henriksen M, Solberg IC, Smastuen MC, Moum BA. Malignancies in patients with inflammatory bowel disease: results from 20 years of follow-up in the IBSEN study. J Crohn's Colitis 2016
5 Kappelman MD, Farkas DK, Long MD. , et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol 2014; 12 (02) 265-273.e1
6 Jussila A, Virta LJ, Pukkala E, Färkkilä MA. Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. Scand J Gastroenterol 2013; 48 (12) 1405-1413
7 Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 2010; 105 (07) 1480-1487
8 van den Heuvel TR, Wintjens DS, Jeuring SF. , et al. Inflammatory bowel disease, cancer and medication: cancer risk in the Dutch population-based IBDSL cohort. Int J Cancer 2016; 139 (06) 1270-1280
9 Caini S, Bagnoli S, Palli D. , et al. Total and cancer mortality in a cohort of ulcerative colitis and Crohn's disease patients: the Florence Inflammatory Bowel Disease study, 1978-2010. Dig Liver Dis 2016; 48 (10) 1162-1167
10 Biancone L, Zuzzi S, Ranieri M. , et al. Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study. J Crohn's Colitis 2012; 6 (05) 578-587
11 Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011; 141 (05) 1612-1620
12 Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012; 143 (02) 390-399.e1
13 Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8 (03) 268-274
14 Elriz K, Carrat F, Carbonnel F, Marthey L, Bouvier AM, Beaugerie L. ; CESAME Study Group. Incidence, presentation, and prognosis of small bowel adenocarcinoma in patients with small bowel Crohn's disease: a prospective observational study. Inflamm Bowel Dis 2013; 19 (09) 1823-1826
15 Caspersen S, Elkjaer M, Riis L. , et al; Danish Crohn Colitis Database. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008; 6 (11) 1212-1217 , quiz 1176
16 Fidder H, Schnitzler F, Ferrante M. , et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58 (04) 501-508
17 Katsanos KH, Roda G, Brygo A, Delaporte E, Colombel JF. Oral cancer and oral precancerous lesions in inflammatory bowel diseases: a systematic review. J Crohn's Colitis 2015; 9 (11) 1043-1052
18 Wadhwa V, Lopez R, Shen B. Crohn's disease is associated with the risk for thyroid cancer. Inflamm Bowel Dis 2016; 22 (12) 2902-2906
19 Hutfless S, Fireman B, Kane S, Herrinton LJ. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28 (05) 598-605
20 Goldacre MJ, Wotton CJ, Yeates D, Seagroatt V, Jewell D. Cancer in patients with ulcerative colitis, Crohn's disease and coeliac disease: record linkage study. Eur J Gastroenterol Hepatol 2008; 20 (04) 297-304
21 Nissen LH, Assendorp EL, van der Post RS. , et al. Impaired gastric cancer survival in patients with inflammatory bowel disease. J Gastrointestin Liver Dis 2016; 25 (04) 431-440
22 Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009; 249 (01) 63-71
23 Ruffolo C, Scarpa M, Polese L. , et al. Clinical presentation and diagnosis of intestinal adenocarcinoma in Crohn's disease: analysis of clinical predictors and of the life-time risk. J Gastrointest Surg 2010; 14 (11) 1746-1751
24 Cahill C, Gordon PH, Petrucci A, Boutros M. Small bowel adenocarcinoma and Crohn's disease: any further ahead than 50 years ago?. World J Gastroenterol 2014; 20 (33) 11486-11495
25 Palascak-Juif V, Bouvier AM, Cosnes J. , et al. Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo. Inflamm Bowel Dis 2005; 11 (09) 828-832
26 von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum 2007; 50 (06) 839-855
27 Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen TI. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005; 100 (12) 2724-2729
28 Laukoetter MG, Mennigen R, Hannig CM. , et al. Intestinal cancer risk in Crohn's disease: a meta-analysis. J Gastrointest Surg 2011; 15 (04) 576-583
29 Taleban S, Elquza E, Gower-Rousseau C, Peyrin-Biroulet L. Cancer and inflammatory bowel disease in the elderly. Dig Liver Dis 2016; 48 (10) 1105-1111
30 Egan L, D'Inca R, Jess T. , et al. Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (II). J Crohn's Colitis 2014; 8 (01) 19-30
31 Wieghard N, Mongoue-Tchokote S, Young JI, Sheppard BC, Tsikitis VL. Prognosis of small bowel adenocarcinoma in Crohn's disease compares favourably with de novo small bowel adenocarcinoma. Colorectal Dis 2017; 19 (05) 446-455
32 Kristo I, Riss S, Argeny S, Maschke S, Chitsabesan P, Stift A. Incidental adenocarcinoma in patients undergoing surgery for stricturing Crohn's disease. World J Gastroenterol 2017; 23 (03) 472-477
33 Widmar M, Greenstein AJ, Sachar DB, Harpaz N, Bauer JJ, Greenstein AJ. Small bowel adenocarcinoma in Crohn's disease. J Gastrointest Surg 2011; 15 (05) 797-802
34 Nesbit Jr RR, Elbadawi NA, Morton JH, Cooper Jr RA. Carcinoma of the small bowel. A complication of regional enteritis. Cancer 1976; 37 (06) 2948-2959
35 Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 2004; 101 (03) 518-526
36 Zagorowicz ES, Pietrzak AM, Wronska E. , et al. Small bowel tumors detected and missed during capsule endoscopy: single center experience. World J Gastroenterol 2013; 19 (47) 9043-9048
37 Piton G, Cosnes J, Monnet E. , et al. Risk factors associated with small bowel adenocarcinoma in Crohn's disease: a case-control study. Am J Gastroenterol 2008; 103 (07) 1730-1736
38 Butnor KJ, Pavlisko EN, Sporn TA, Roggli VL. Malignant peritoneal mesothelioma and Crohn disease. J Clin Pathol 2017; 70 (03) 228-232
39 Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011; 54 (01) 173-184
40 Loftus Jr EV, Harewood GC, Loftus CG. , et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54 (01) 91-96
41 Ananthakrishnan AN, Cagan A, Gainer VS. , et al. Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. J Crohn's Colitis 2014; 8 (09) 956-963
42 de Valle MB, Björnsson E, Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int 2012; 32 (03) 441-448
43 Erichsen R, Jepsen P, Vilstrup H, Ekbom A, Sørensen HT. Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978-2003. Eur J Epidemiol 2009; 24 (09) 513-520
44 Huai JP, Ding J, Ye XH, Chen YP. Inflammatory bowel disease and risk of cholangiocarcinoma: evidence from a meta-analysis of population-based studies. Asian Pac J Cancer Prev 2014; 15 (08) 3477-3482
45 Lennerz JK, van der Sloot KW, Le LP. , et al. Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. Int J Colorectal Dis 2016; 31 (05) 973-982
46 Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48 (04) 526-535
47 Gillen CD, Andrews HA, Prior P, Allan RN. Crohn's disease and colorectal cancer. Gut 1994; 35 (05) 651-655
48 Fornaro R, Caratto M, Caratto E. , et al. Colorectal cancer in patients with inflammatory bowel disease: the need for a real surveillance program. Clin Colorectal Cancer 2016; 15 (03) 204-212
49 Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 2006; 23 (08) 1097-1104
50 Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 1994; 35 (07) 950-954
51 Lindström L, Lapidus A, Ost A, Bergquist A. Increased risk of colorectal cancer and dysplasia in patients with Crohn's colitis and primary sclerosing cholangitis. Dis Colon Rectum 2011; 54 (11) 1392-1397
52 Higashi D, Katsuno H, Kimura H. , et al. Current state of and problems related to cancer of the intestinal tract associated with Crohn's disease in Japan. Anticancer Res 2016; 36 (07) 3761-3766
53 Ording AG, Horváth-Puhó E, Erichsen R. , et al. Five-year mortality in colorectal cancer patients with ulcerative colitis or Crohn's disease: a nationwide population-based cohort study. Inflamm Bowel Dis 2013; 19 (04) 800-805
54 Ali HR, Dawson SJ, Blows FM, Provenzano E, Pharoah PD, Caldas C. Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res 2011; 13 (06) R118
55 Axelrad J, Kriplani A, Ozbek U. , et al. Chemotherapy tolerance and oncologic outcomes in patients with colorectal cancer with and without inflammatory bowel disease. Clin Colorectal Cancer 2017; 16 (03) e205-e210
56 Manninen P, Karvonen AL, Huhtala H. , et al. The risk of colorectal cancer in patients with inflammatory bowel diseases in Finland: a follow-up of 20 years. J Crohn's Colitis 2013; 7 (11) e551-e557
57 Basseri RJ, Basseri B, Papadakis KA. Dysplasia and cancer in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2011; 5 (01) 59-66
58 Itzkowitz SH, Present DH. ; Crohn's and Colitis Foundation of America Colon Cancer in IBD Study Group. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11 (03) 314-321
59 Maykel JA, Hagerman G, Mellgren AF. , et al. Crohn's colitis: the incidence of dysplasia and adenocarcinoma in surgical patients. Dis Colon Rectum 2006; 49 (07) 950-957
60 Winkler R, Wittmer A, Heusermann U. Cancer and Crohn's disease [in German]. Z Gastroenterol 2002; 40 (08) 569-576
61 Thomas M, Bienkowski R, Vandermeer TJ, Trostle D, Cagir B. Malignant transformation in perianal fistulas of Crohn's disease: a systematic review of literature. J Gastrointest Surg 2010; 14 (01) 66-73
62 Slesser AA, Bhangu A, Bower M, Goldin R, Tekkis PP. A systematic review of anal squamous cell carcinoma in inflammatory bowel disease. Surg Oncol 2013; 22 (04) 230-237
63 Wisniewski A, Fléjou JF, Siproudhis L, Abramowitz L, Svrcek M, Beaugerie L. Anal neoplasia in inflammatory bowel disease: classification proposal, epidemiology, carcinogenesis, and risk management perspectives. J Crohn's Colitis 2017; 11 (08) 1011-1018
64 Askling J, Brandt L, Lapidus A. , et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005; 54 (05) 617-622
65 Bernstein CN. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 2001; 3 (06) 477-483
66 Magro F, Peyrin-Biroulet L, Sokol H. , et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohn's Colitis 2014; 8 (01) 31-44
67 Beaugerie L, Brousse N, Bouvier AM. , et al; CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374 (9701): 1617-1625
68 Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54 (08) 1121-1125
69 Jess T, Horváth-Puhó E, Fallingborg J, Rasmussen HH, Jacobsen BA. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol 2013; 108 (12) 1869-1876
70 Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2014; 39 (05) 447-458
71 Bourrier A, Carrat F, Colombel JF. , et al; CESAME Study Group. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Aliment Pharmacol Ther 2016; 43 (02) 252-261
72 Osterman MT, Sandborn WJ, Colombel JF. , et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology 2014; 146 (04) 941-949
73 Nyboe Andersen N, Pasternak B, Basit S. , et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 2014; 311 (23) 2406-2413